The gene synthesis service market size was USD 585 million in 2023 and is expected to be valued at USD 3138.64 million by 2034, expanding at a compound annual growth rate (CAGR) of 16.5% between 2024 and 2034.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5272
Market Overview
The gene synthesis service market is growing rapidly as a result of the rise of synthetic biology. Synthetic biology involves synthesizing genetic components in the laboratory. This multidisciplinary process plays a crucial role in the field of life science and has become necessary to gain insights into genes for the creation of synthetic genomes. The National Institutes of Health (NIH) has reported that despite technologies for reading DNA advancing rapidly, the technologies for writing DNA have lagged. However, DNA synthesis technologies vary in their effectiveness at bridging this gap.
The rising investments in biotechnology R&D, advancements in the CRISPR-Cas9 technology, and increasing production of vaccines are expected to drive the growth of the gene synthesis market in the coming years. Moreover, government funding in advancing the healthcare system can have a positive impact on the market. For instance, in September 2024, the National Institutes of Health (NIH) awarded US$ 5.4 million in first-year funding to establish a new program that supports the integration of genomics into learning health systems. Moreover, the rising demand for personalized therapeutics and increasing drug discovery and development fuel market growth.
Major Trends in the Gene Synthesis Service Market
- Increasing Emphasis on Individualized Therapy: With the growing focus on personalized therapeutics, there is a high need for genome mapping to find synthetic genes that correspond to specific genotypes. Synthetic genes help to create targeted treatments and are effective for complex diseases, particularly cancer and rare diseases. According to a report published by NIH in 2023, over 5,000 gene therapy trials are listed with NIH. This number highlights a significant increase in new trials that incorporate chimeric antigen receptor (CAR) T-cell therapies and human genomic editing. Moreover, gene synthesis is important in personalized medicine.
- Innovations and Developments in Synthetic Biology: Advancements in gene synthesis technology create immense opportunities in the gene synthesis service market. Incorporating computer technologies and artificial intelligence has automated the synthesis process, enhancing accuracy and efficiency. Furthermore, the integration of AI has also enhanced the precision of the synthesis technology by reducing errors. This enables the production of complex genes.
- Rising Investments in Gene Therapy: There is a significant increase in funding provided by governments and institutions to accelerate the development of gene therapy. Gene synthesis is essential in gene therapy for activating genes. In addition, the rising investments in pharmaceutical and biotechnology research and developments and the increasing investments in drug development are likely to boost market growth.
Get the latest insights on healthcare industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
Regional Insights
North America’s Sustain Dominance in the Market
North America led the gene synthesis service market with the largest share in 2023. This is due to its well-established biotechnology and healthcare industries, increased government support, and the presence of many market players. In 2022, the US government increased funding in synthetic biology research to USD 161 million. Over the past five years, total public funding has reached USD 820 million, with a focus on gene therapy, precision medicine, and vaccines. The rising investments in drug discovery, personalized medicine, and public-private partnership initiatives further contributed to the region’s dominance.
Increasing Investments in R&D to Boost the Market in Asia Pacific
The market in Asia Pacific is expected to grow at the fastest rate in the coming years due to the increasing investments in the R&D. Moreover, governments of Asian countries are investing heavily in advancing their healthcare system. According to the Johns Hopkins Center for Health Security, China has made significant investments in synthetic biology through various programs. According to the Ministry of Science and Technology of China, investments in gene synthesis and associated technologies will increase by 20% per year over the next ten years. Additionally, APBioNET supports the advancement of bioinformatics in research and education through training programs, workshops, symposia, and conferences, contributing to regional market growth.
Market Segmentation
By type, the below 1000 bp segment dominated the gene synthesis service market in 2023. The segmental dominance is mainly attributed to its lower turnaround time compared to longer gene sequences.
By application, the commercial segment led the global market in 2023. This is mainly due to advanced research and development facilities equipped with specialized tools. The rise in need for faster and precise research outcomes further bolstered the demand for gene synthesis services. On the other hand, the academic research segment is projected to witness significant growth during the forecast period. Due to the absence of specialized gene synthesis facilities, the reliance on external gene synthesis services is rising, contributing to segmental growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Competitive Landscape
The gene synthesis service market is highly competitive, with a large number of key players operating in the market. Some of the major market players include Ansa Biotechnologies, Ltd., ATUM, Azenta Life Sciences, DNA Script, Eurofins Genomics, GeneArt, GenScript Biotech Corporation, Integrated DNA Technologies, SGI-DNA, Synthetic Genomics, Thermo Fisher Scientific, and Twist Bioscience Corporation, which are focusing on technological advancements, strategic collaborations, and service expansions.
- In August 2024, ATUM, a leading US-based provider of integrated biologics solutions, launched the CHO-K1-derived discoCHO cell line for transient protein production.
- In July 2024, Ansa Biotechnologies announced the commercial availability of its Ansa Clonal DNA and Ansa DNA Fragments, providing advanced solutions for precise and efficient DNA synthesis.
- In May 2024, Azenta, Inc. celebrated the grand opening of its new Genomics Laboratory in Oxford, UK. This expansion strengthens the company’s global presence and enhances the availability of GENEWIZ Multiomics & Synthesis Solutions in the UK market.
Recent Developments
- In September 2024, The Center for Health Security introduced the Gene Synthesis Screening Information Hub, an online platform designed to assist nucleic acid synthesis providers, manufacturers, and customers in complying with a new federal framework. The platform aims to prevent the misuse of synthetic nucleic acids and promote safe scientific research practices across the United States.
- In November 2023, Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, launched Twist Express Genes, a new leading gene synthesis service with an order to shipping turnaround time of five to seven business days.
- In June 2024, GenScript Biotech Corporation, a pioneer in synthetic biology, announced the launch of its flagship GenScript FLASH Gene service. This ultra-fast sequence-to-plasmid (S2P) service addresses the rising demand for rapid, high-quality, and cost-efficient delivery of gene constructs.
- In March 2024, Integrated DNA Technologies (IDT) expanded its gene synthesis offerings with a new custom vector onboarding tool. This user-friendly solution allows researchers to bypass in-house cloning steps and access 100% sequence-verified clonal DNA for functional studies. By submitting vector sequences directly through IDT’s website, researchers eliminate the need for intermediary communication, streamlining the process.
- In December 2023, Evonetix Ltd., a company advancing semiconductor-scale technology for improved gene synthesis, signed a joint development and commercial supply agreement with Analog Devices, Inc. (ADI), a global semiconductor leader. This partnership marks a new phase in their collaboration, aimed at setting a technological benchmark to address the global demand for more efficient gene synthesis solutions.
Browse More Insights of Towards Healthcare:
The global arthroscopy devices market is valued at USD 25.03 billion in 2024, and it's expected to grow to USD 56.75 billion by 2034, with a CAGR of 8.53% from 2024 to 2034.
The global atrial fibrillation treatment market is valued at USD 24.26 billion in 2024 and will likely reach USD 40.27 billion by 2034, growing at a CAGR of 5.2% over the next decade.
The bionic eye market is estimated at USD 109.06 million in 2024 and could grow to USD 255.59 million by 2034, with a CAGR of 8.89% from 2024 to 2034.
The metabolomics market was valued at USD 2.83 billion in 2023 and is projected to reach USD 11.32 billion by 2034, expanding at a CAGR of 13.43% from 2024 to 2034.
The cell counting market was valued at USD 9.45 billion in 2023, and it is expected to grow to USD 22.85 billion by 2034, with a CAGR of 8.41% over the next decade.
The miRNA sequencing and assay market is valued at USD 391.73 million in 2024, and it's projected to reach USD 1.37 billion by 2034, growing at a CAGR of 13.33% from 2024 to 2034.
The healthcare IT market was valued at USD 238.30 billion in 2023 and is expected to grow to USD 1.40 trillion by 2034, expanding at a CAGR of 17.5% from 2024 to 2034.
The electronic health records market is valued at USD 28.60 billion in 2024, and it is projected to reach USD 43.66 billion by 2034, growing at a CAGR of 4.32% from 2024 to 2034.
The cell separation technologies market is valued at USD 15.84 billion in 2024 and is expected to grow to USD 67.75 billion by 2034, with a CAGR of 15.64% from 2024 to 2034.
The medical imaging informatics market was estimated at USD 5.5 billion in 2023 and is projected to grow to USD 11.4 billion by 2034, expanding at a CAGR of 6.85% from 2024 to 2034.
Top Companies in the Gene Synthesis Service Market
- Ansa Biotechnologies, Ltd.
- ATUM
- Azenta Life Sciences
- DNA Script
- Eurofins Genomics
- GeneArt
- GenScript Biotech Corporation
- Integrated DNA Technologies
- SGI-DNA
- Synthetic Genomics
- Thermo Fisher Scientific
- Twist Bioscience Corporation
Segments Covered in the Report
By Type
- Below 1000 bp
- 1001 to 3000 bp
- 3001 to 5000 bp
- Above 5000 bp
By Application
- Commercial
- Academic Research
By Region
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa (MEA)
View-indepth TOC of Gene Synthesis Service Market: https://www.towardshealthcare.com/table-of-content/gene-synthesis-service-market-sizing
Acquire our comprehensive analysis today @ https://www.towardshealthcare.com/price/5272
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Gain access to the latest insights and statistics in the healthcare industry by subscribing to our Annual Membership. Stay updated on healthcare industry segmentation with detailed reports, market trends, and expert analysis tailored to your needs. Stay ahead of the curve with valuable resources and strategic recommendations. Join today to unlock a wealth of knowledge and opportunities in the dynamic world of healthcare: Get a Subscription
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Browse our Brand-New Journals:
https://www.towardspackaging.com
https://www.towardsautomotive.com
https://www.precedenceresearch.com
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Get Our Freshly Printed Chronicle: https://www.healthcarewebwire.com
